Stock Analysis on Net

Pfizer Inc. (NYSE:PFE)

DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin 

Microsoft Excel

Two-Component Disaggregation of ROE

Pfizer Inc., decomposition of ROE

Microsoft Excel
ROE = ROA × Financial Leverage
Dec 31, 2025 8.99% = 3.73% × 2.41
Dec 31, 2024 9.11% = 3.76% × 2.42
Dec 31, 2023 2.38% = 0.94% × 2.54
Dec 31, 2022 32.79% = 15.91% × 2.06
Dec 31, 2021 28.47% = 12.11% × 2.35

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).


The period under review demonstrates significant fluctuations in financial performance, particularly concerning profitability and leverage. Return on Equity (ROE) experienced a marked decline from 2022 to 2023, followed by a period of relative stabilization, albeit at considerably lower levels than initially observed. This trend is intricately linked to the performance of Return on Assets (ROA) and the degree of Financial Leverage employed.

Return on Assets (ROA)
ROA exhibited a substantial increase from 12.11% in 2021 to 15.91% in 2022. However, this positive momentum was reversed in 2023, with ROA plummeting to 0.94%. A modest recovery occurred in 2024 and 2025, reaching 3.76% and 3.73% respectively, indicating a stabilization but remaining significantly below the levels seen in 2021 and 2022. This suggests a weakening in the efficiency with which assets are being utilized to generate earnings.
Financial Leverage
Financial Leverage decreased from 2.35 in 2021 to 2.06 in 2022, indicating a reduction in the use of debt financing. It then increased to 2.54 in 2023, before decreasing slightly to 2.42 in 2024 and stabilizing at 2.41 in 2025. The fluctuations in leverage suggest a dynamic approach to capital structure management, potentially in response to changing profitability or investment opportunities.
Return on Equity (ROE) – Two-Component Disaggregation
The decline in ROE from 32.79% in 2022 to 2.38% in 2023 is primarily attributable to the dramatic decrease in ROA. While financial leverage increased in 2023, this increase was insufficient to offset the negative impact of the lower asset profitability. The subsequent stabilization of ROE in 2024 and 2025, at approximately 9%, reflects the combined effect of a modestly improving ROA and relatively stable financial leverage. The initial high ROE was heavily influenced by both a strong ROA and a moderate level of financial leverage. The subsequent period demonstrates a significant reduction in the contribution of asset efficiency to overall equity returns.

In summary, the observed trends indicate a period of declining profitability, as measured by ROA, which significantly impacted ROE. While adjustments in financial leverage were made, they were not sufficient to maintain the higher levels of ROE experienced in the earlier part of the period. The recent stabilization suggests a potential bottoming out of performance, but further monitoring is required to assess the sustainability of this trend.

AI Ask an analyst for more


Three-Component Disaggregation of ROE

Pfizer Inc., decomposition of ROE

Microsoft Excel
ROE = Net Profit Margin × Asset Turnover × Financial Leverage
Dec 31, 2025 8.99% = 12.42% × 0.30 × 2.41
Dec 31, 2024 9.11% = 12.62% × 0.30 × 2.42
Dec 31, 2023 2.38% = 3.56% × 0.26 × 2.54
Dec 31, 2022 32.79% = 31.01% × 0.51 × 2.06
Dec 31, 2021 28.47% = 26.76% × 0.45 × 2.35

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).


The period under review demonstrates significant fluctuations in the key components of Return on Equity (ROE). A notable divergence emerges when examining the trends in Net Profit Margin, Asset Turnover, and Financial Leverage, which collectively influence overall profitability and efficiency.

Net Profit Margin
The Net Profit Margin exhibited an initial increase from 26.76% in 2021 to a peak of 31.01% in 2022. However, a substantial decline followed, reaching a low of 3.56% in 2023. A partial recovery is then observed in 2024 and 2025, with margins stabilizing around 12.62% and 12.42% respectively. This suggests a period of strong profitability followed by significant challenges, and a subsequent, though incomplete, restoration of earnings power.
Asset Turnover
Asset Turnover showed an improvement from 0.45 in 2021 to 0.51 in 2022, indicating increased efficiency in utilizing assets to generate sales. However, similar to the Net Profit Margin, this metric experienced a considerable decrease to 0.26 in 2023. The ratio remained relatively stable at 0.30 for both 2024 and 2025, suggesting a persistent reduction in asset utilization efficiency compared to earlier periods.
Financial Leverage
Financial Leverage, representing the extent to which the company utilizes debt financing, decreased from 2.35 in 2021 to 2.06 in 2022. It then increased to 2.54 in 2023, before moderating slightly to 2.42 in 2024 and 2.41 in 2025. This indicates a fluctuating reliance on debt, with a recent trend towards increased leverage.
Return on Equity (ROE)
ROE mirrored the trends observed in its component ratios. It rose from 28.47% in 2021 to 32.79% in 2022, then plummeted to 2.38% in 2023. A modest recovery occurred in 2024 and 2025, with ROE reaching 9.11% and 8.99% respectively. The substantial decline in ROE in 2023 directly correlates with the simultaneous decreases in Net Profit Margin and Asset Turnover, despite an increase in Financial Leverage.

The analysis reveals a clear pattern: a period of positive performance in 2022 was followed by a significant downturn in 2023, impacting overall profitability as measured by ROE. While some recovery is evident in the subsequent years, the levels of Net Profit Margin, Asset Turnover, and ROE remain below their 2022 peaks. The interplay between these components suggests that the company’s ability to generate profits from its assets, and its reliance on financial leverage, are key drivers of its overall return to shareholders.

AI Ask an analyst for more


Five-Component Disaggregation of ROE

Pfizer Inc., decomposition of ROE

Microsoft Excel
ROE = Tax Burden × Interest Burden × EBIT Margin × Asset Turnover × Financial Leverage
Dec 31, 2025 8.99% = 1.04 × 0.74 × 16.26% × 0.30 × 2.41
Dec 31, 2024 9.11% = 1.00 × 0.72 × 17.44% × 0.30 × 2.42
Dec 31, 2023 2.38% = 2.11 × 0.31 × 5.40% × 0.26 × 2.54
Dec 31, 2022 32.79% = 0.90 × 0.97 × 35.52% × 0.51 × 2.06
Dec 31, 2021 28.47% = 0.92 × 0.95 × 30.58% × 0.45 × 2.35

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).


The five-component DuPont analysis reveals significant shifts in performance metrics between 2021 and 2025. Return on Equity (ROE) experienced a substantial decline over the period, accompanied by notable fluctuations in its underlying components. A detailed examination of these components provides insight into the drivers of this change.

Return on Equity (ROE)
ROE began at 28.47% in 2021, peaked at 32.79% in 2022, and then dramatically decreased to 2.38% in 2023. A slight recovery occurred in 2024 and 2025, with ROE stabilizing around 9.0%.
EBIT Margin
The EBIT Margin demonstrated an initial increase from 30.58% in 2021 to 35.52% in 2022. However, this was followed by a sharp contraction to 5.40% in 2023. The margin then rebounded to 17.44% in 2024 and remained relatively stable at 16.26% in 2025. This volatility significantly impacted overall profitability.
Asset Turnover
Asset Turnover decreased from 0.45 in 2021 to 0.26 in 2023, indicating a reduced efficiency in utilizing assets to generate sales. A modest increase to 0.30 was observed in both 2024 and 2025, but the ratio remained below the levels seen in the earlier years.
Financial Leverage
Financial Leverage exhibited a slight decrease from 2.35 in 2021 to 2.06 in 2022, before increasing to 2.54 in 2023. It then stabilized around 2.42 and 2.41 in 2024 and 2025, respectively. While leverage increased overall, its impact on ROE was overshadowed by changes in profitability and asset utilization.
Tax Burden
The Tax Burden fluctuated considerably. It was relatively stable at approximately 0.90-0.92 in 2021 and 2022, then increased substantially to 2.11 in 2023. It subsequently decreased to 1.00 in 2024 and 1.04 in 2025, suggesting changes in the effective tax rate or taxable income.
Interest Burden
The Interest Burden decreased significantly from 0.95 in 2021 to 0.31 in 2023, indicating a reduced proportion of earnings allocated to interest expense. It then increased to 0.72 in 2024 and 0.74 in 2025, but remained below the initial levels. This suggests improved debt management or a change in the cost of debt.

The substantial decline in ROE from 2022 to 2023 appears primarily driven by the dramatic reduction in EBIT Margin and Asset Turnover. While Financial Leverage remained relatively stable, the combined effect of lower profitability and asset efficiency significantly reduced the return generated on equity. The subsequent stabilization of ROE in 2024 and 2025 suggests a partial recovery in profitability and asset utilization, though levels remain considerably lower than those observed in 2021 and 2022.

AI Ask an analyst for more


Two-Component Disaggregation of ROA

Pfizer Inc., decomposition of ROA

Microsoft Excel
ROA = Net Profit Margin × Asset Turnover
Dec 31, 2025 3.73% = 12.42% × 0.30
Dec 31, 2024 3.76% = 12.62% × 0.30
Dec 31, 2023 0.94% = 3.56% × 0.26
Dec 31, 2022 15.91% = 31.01% × 0.51
Dec 31, 2021 12.11% = 26.76% × 0.45

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).


The financial performance, as indicated by the provided metrics, exhibits significant fluctuations over the five-year period. Return on Assets (ROA) demonstrates a marked decline from 2021 to 2023, followed by a modest recovery in the subsequent two years. This ROA movement is directly attributable to shifts in both Net Profit Margin and Asset Turnover.

Net Profit Margin
The Net Profit Margin initially increased from 26.76% in 2021 to 31.01% in 2022, indicating improved profitability. However, a substantial decrease occurred in 2023, falling to 3.56%. The margin partially recovered in 2024 and 2025, stabilizing around 12.62% and 12.42% respectively. This suggests a period of significantly reduced earnings power followed by a partial rebound.
Asset Turnover
Asset Turnover shows an initial increase from 0.45 in 2021 to 0.51 in 2022, suggesting improved efficiency in utilizing assets to generate sales. A considerable decline is then observed in 2023, dropping to 0.26, indicating a reduced ability to generate sales from its asset base. The ratio remains relatively stable at 0.30 for both 2024 and 2025, suggesting limited improvement in asset utilization following the 2023 decline.

The substantial drop in ROA in 2023 is a direct consequence of the combined negative impacts of both a significantly lower Net Profit Margin and a reduced Asset Turnover. While both metrics experienced some recovery in 2024 and 2025, the ROA remained considerably below the levels observed in 2021 and 2022. The stabilization of Asset Turnover in the latter two years, coupled with a relatively stable Net Profit Margin, resulted in a corresponding stabilization of ROA.

ROA Disaggregation
The two-component disaggregation of ROA clearly illustrates the drivers of performance. The initial strong ROA in 2021 and 2022 was supported by both healthy profitability and efficient asset utilization. The subsequent decline in 2023 highlights the sensitivity of ROA to changes in either or both of these components. The limited recovery in ROA from 2023 to 2025 suggests that improvements in profitability and asset utilization have not been sufficient to restore performance to prior levels.

Overall, the period under review demonstrates a significant shift in financial performance, characterized by a substantial decline in ROA driven by concurrent decreases in profitability and asset utilization, followed by a period of stabilization at a lower performance level.

AI Ask an analyst for more


Four-Component Disaggregation of ROA

Pfizer Inc., decomposition of ROA

Microsoft Excel
ROA = Tax Burden × Interest Burden × EBIT Margin × Asset Turnover
Dec 31, 2025 3.73% = 1.04 × 0.74 × 16.26% × 0.30
Dec 31, 2024 3.76% = 1.00 × 0.72 × 17.44% × 0.30
Dec 31, 2023 0.94% = 2.11 × 0.31 × 5.40% × 0.26
Dec 31, 2022 15.91% = 0.90 × 0.97 × 35.52% × 0.51
Dec 31, 2021 12.11% = 0.92 × 0.95 × 30.58% × 0.45

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).


The period under review demonstrates significant fluctuations in key financial ratios impacting overall Return on Assets (ROA). A notable divergence in performance is observed between 2021-2022 and 2023-2025. Initial improvements in profitability and efficiency are followed by a substantial decline, with a partial recovery in the most recent periods.

Return on Assets (ROA)
ROA exhibits a strong increase from 12.11% in 2021 to 15.91% in 2022. However, this is followed by a dramatic decrease to 0.94% in 2023. A modest recovery is then seen, with ROA reaching 3.76% in 2024 and remaining relatively stable at 3.73% in 2025. This pattern suggests a significant shift in the company’s ability to generate earnings from its assets.
EBIT Margin
The EBIT Margin mirrors the ROA trend, increasing from 30.58% in 2021 to 35.52% in 2022, before plummeting to 5.40% in 2023. Subsequent years show improvement, reaching 17.44% in 2024 and 16.26% in 2025, though not returning to the levels seen in 2021-2022. This indicates a substantial change in core operational profitability.
Asset Turnover
Asset Turnover declines from 0.45 in 2021 to 0.26 in 2023, coinciding with the drop in ROA and EBIT Margin. A slight increase to 0.30 is observed in both 2024 and 2025, but remains below the initial level. This suggests a reduced efficiency in utilizing assets to generate sales.
Tax Burden
The Tax Burden fluctuates considerably. It remains relatively stable around 0.90-0.92 in 2021 and 2022, then increases sharply to 2.11 in 2023, before decreasing to 1.00 in 2024 and 1.04 in 2025. This variation likely reflects changes in tax liabilities and effective tax rates, potentially impacting net income and, consequently, ROA.
Interest Burden
The Interest Burden decreases significantly from 0.95 in 2021 to 0.31 in 2023. It then rises to 0.72 in 2024 and 0.74 in 2025. This suggests a change in the company’s debt levels or interest expense, with a notable reduction in the financial impact of interest payments in 2023, followed by a partial reversal.

The substantial decline in ROA in 2023 appears to be driven by a combination of factors: a significant reduction in EBIT Margin and a decrease in Asset Turnover. While the Tax and Interest Burdens also experienced changes, their impact appears secondary to the operational performance and asset utilization issues. The partial recovery in 2024 and 2025 suggests some corrective actions were taken, but the company has not yet regained its previous levels of profitability and efficiency.

AI Ask an analyst for more


Disaggregation of Net Profit Margin

Pfizer Inc., decomposition of net profit margin ratio

Microsoft Excel
Net Profit Margin = Tax Burden × Interest Burden × EBIT Margin
Dec 31, 2025 12.42% = 1.04 × 0.74 × 16.26%
Dec 31, 2024 12.62% = 1.00 × 0.72 × 17.44%
Dec 31, 2023 3.56% = 2.11 × 0.31 × 5.40%
Dec 31, 2022 31.01% = 0.90 × 0.97 × 35.52%
Dec 31, 2021 26.76% = 0.92 × 0.95 × 30.58%

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).


An examination of the provided financial metrics reveals significant fluctuations in profitability components between 2021 and 2025. The period is characterized by initial strength followed by a substantial decline and subsequent partial recovery. The analysis focuses on the interplay between tax burden, interest burden, EBIT margin, and net profit margin.

Net Profit Margin
The net profit margin experienced a decrease from 26.76% in 2021 to 3.56% in 2023, representing a considerable contraction. A partial recovery is then observed, with the margin increasing to 12.62% in 2024 and remaining relatively stable at 12.42% in 2025. This suggests a period of significant operational or financial challenges in 2023, followed by improvements in subsequent years.
EBIT Margin
The EBIT margin mirrors the initial decline in net profit margin, falling dramatically from 30.58% in 2021 to 5.40% in 2023. Similar to the net profit margin, the EBIT margin demonstrates improvement in 2024 (17.44%) and 2025 (16.26%), though it does not fully recover to its 2021 level. This indicates that operational profitability was significantly impacted during 2023.
Tax Burden
The tax burden exhibits a notable increase from 0.92 in 2021 to 2.11 in 2023, before stabilizing at 1.00 and 1.04 in 2024 and 2025, respectively. The spike in 2023 likely contributed to the decline in net profit margin, as a higher tax burden reduces after-tax profits. The subsequent stabilization suggests a change in tax circumstances or effective tax rate.
Interest Burden
The interest burden decreased substantially from 0.95 in 2021 to 0.31 in 2023. This reduction in interest expense likely provided some offset to the declining EBIT margin during that period. However, the interest burden then increased to 0.72 and 0.74 in 2024 and 2025, respectively, potentially indicating increased borrowing or changes in interest rates. The impact of this increase on net profit margin is less pronounced than the tax burden changes.

In summary, the period under review was marked by a significant downturn in profitability in 2023, driven primarily by a decline in the EBIT margin and a substantial increase in the tax burden. While both metrics showed improvement in 2024 and 2025, they did not fully return to their 2021 levels. The interest burden provided a mitigating factor in 2023 but increased modestly in the later years.

AI Ask an analyst for more